Omega Laboratories Limited offers a complete range of potentially exclusive sclerosing products.

Since its introduction in the 50s, SCLEROTHERAPY has improved continuously thanks to constant technical improvements and knowledge sharing. In Canada, Omega Laboratories Limited has been offering a complete line of sclerosing products made in accordance with the most advanced technological standards for over 25 years. We are involved in the training process through our various presentations to the Canadian Society of Phlebology of which we are a corporate member.


 Sclerodex ®
Sclerodex.png 5 vials of 10 mL
Dextrose USP 250 mg/mL
Sodium Chloride USP 100 mg/mL

SCLERODEX® is a relatively weak sclerosant recommended for the local treatment of varicose veins, especially small vessels and communicating veins of the superficial venous system. It is also used as an adjunct to the surgical treatment of varicose veins of the lower limbs. Sclerodex is a mild sclerosing solution.
Depends on the length and size of the vein to be sclerosed. Do not inject more than 10 mL per visit, at the rate of 0.1 to 1 mL maximum per injection site; keep a 5 cm space between injection sites.
See prescribing information.

Bouton-Download17px.png Download the Product Monograph PDF

 Tromboject ®

Sodium Tetradecyl Sulfate,
Omega Standard

10 mg/mL 10 vials of 2 mL
30 mg/mL 10 vials of 2 mL
30 mg/mL 5 vials of 5 mL

TROMBOJECT®  is primarily used in the treatment of varicose veins of the legs by compression sclerotherapy. Sodium tetradecyl sulfate causes a direct irritation of the intima and formation of a thrombus, while compression promotes the occlusion of the vein by fibrosis.
The concentration to be used and the dosage range depend on the size and the length of the veins to be treated.
Usual doses:
Small veins:
0.5 to 2 mL of the 10 mg/mL solution
Medium or large veins:
0.5 to 2 mL of 30 mg/mL solution
The smallest possible volume has to be injected, slowly and by the IV route. Do not inject more than 2 mL of either concentration into a single varicosity; respect a 5 cm interval between two injection sites. Do not inject more than 3 mL of the 30 mg/mL solution per visit. The recommended interval between treatments is usuallly 5-7 days.
Strictly contraindicated, as any sclerosing agent, in case of:
• recent superficial or deep thrombophlebitis (6 months to 2 years).
• varicose veins caused by abdominal or pelvic tumors.
• potential underlying arterial disease.
• renal or cardiac insufficiencies accompanied by venous stasis and dilatation.
• angina pectoris.
• local or systemic infections.
• hyperthyroidism.
• uncontrolled diabetes mellitus.
• asthma.
Do not administer to patients with a history of sodium tetradecyl sulfate hypersensitivity.

Safety for use in pregnancy has not been established. Use only when clearly needed and when the potential benefits outweigh the potential hazards to the foetus. It is not know whether sodium tetradecyl sulfate is excreted in human milk. Caution should be exercised when used in nursing mothers.″
See prescribing information.

Bouton-Download17px.png Download the Product Monograph PDF